Bristol Myers Squibb's phase 3 RELATIVITY─098 trial of Opdualag to treat patients with completely resected stage III─IV ...
Bristol Myers Squibb announced the phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free …